Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity

被引:0
|
作者
Ng, Ho Yu [1 ]
Liao, Yunshi [2 ]
Cheung, Ching Lung [3 ,4 ]
Zhang, Ruiqi [5 ]
Chan, Kwok Hung [6 ]
Seto, Wai-Kay [5 ]
Leung, Wai K. [5 ]
Hung, Ivan F. N. [5 ]
Lam, Tommy T. Y. [2 ,4 ,7 ]
Cheung, Ka Shing [5 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[4] Lab Data Discovery Hlth Ltd, 19W Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
[5] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Med, Hong Kong, Peoples R China
[6] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Microbiol, Hong Kong, Peoples R China
[7] Ctr Immunol & Infect Ltd, 17W Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
gut microbiota; vaccine; COVID-19; vaccine immunogenicity; BNT162b2 (Pfizer-BioNTech); B-CELL MEMORY; COVID-19; VACCINE; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; AMINO-ACIDS; CYSTEINE; GLUTATHIONE; METABOLITES; MODULATION; HEALTH;
D O I
10.3389/fimmu.2025.1534787
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.Methods This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites.Results Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb >= 200AU/mL). None had COVID-19 at end of study. Ruminococcus bicirculans (log10LDA score=3.65), Parasutterella excrementihominis (score=2.82) and Streptococcus salivarius (score=2.31) were enriched in high-responders, while Bacteroides thetaiotaomicron was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (R. bicirculans-aOR: 1.87, 95% CI: 1.02-3.51; P. excrementihominis-aOR: 2.2, 95% CI: 1.18-4.18; S. salivarius-aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. R. bicirculans positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response.Conclusion Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors
    Waldhorn, Ithai
    Holland, Roy
    Goshen-Lago, Tal
    Benguigui, Madeleine
    Halberthal, Michael
    Shaked, Yuval
    Ben-Aharon, Irit
    JAMA ONCOLOGY, 2022, 8 (06) : 940 - 941
  • [2] Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF
    Karampitsakos, T.
    Dimeas, I
    Tsiri, P.
    Sotiropoulou, V
    Tomos, I
    Papanikolaou, I
    Katsaras, M.
    Kirgou, P.
    Daniil, Z.
    Gourgoulianis, K.
    Papalexatos, D.
    Sampsonas, F.
    Manali, E.
    Papiris, S.
    Bouros, D.
    Tzouvelekis, A.
    Papaioannoui, o
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [3] Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
    Valentini, Diletta
    Cotugno, Nicola
    Scoppola, Vittorio
    Di Camillo, Chiara
    Colagrossi, Luna
    Manno, Emma Concetta
    Perno, Carlo Federico
    Russo, Cristina
    Palma, Paolo
    Rossi, Paolo
    Villani, Alberto
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (03)
  • [4] Immunogenicity of the BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Is Associated with Medical Conditions
    Guinault, Damien
    Bernier, Matthieu
    Delarche, Antoine
    Neuville, Sylvie
    Milioto, Olivier
    Molinari, Nicolas
    Dahan, Philippe
    NEPHRON, 2022, 146 (06) : 553 - 558
  • [5] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
    Payne, Rebecca P.
    Longet, Stephanie
    Austin, James A.
    Skelly, Donal T.
    Dejnirattisai, Wanwisa
    Adele, Sandra
    Meardon, Naomi
    Faustini, Sian
    Al-Taei, Saly
    Moore, Shona C.
    Tipton, Tom
    Hering, Luisa M.
    Angyal, Adrienn
    Brown, Rebecca
    Nicols, Alexander R.
    Gillson, Natalie
    Dobson, Susan L.
    Amini, Ali
    Supasa, Piyada
    Cross, Andrew
    Bridges-Webb, Alice
    Reyes, Laura Silva
    Linder, Aline
    Sandhar, Gurjinder
    Kilby, Jonathan A.
    Tyerman, Jessica K.
    Altmann, Thomas
    Hornsby, Hailey
    Whitham, Rachel
    Phillips, Eloise
    Malone, Tom
    Hargreaves, Alexander
    Shields, Adrian
    Saei, Ayoub
    Foulkes, Sarah
    Stafford, Lizzie
    Johnson, Sile
    Wootton, Daniel G.
    Conlon, Christopher P.
    Jeffery, Katie
    Matthews, Philippa C.
    Frater, John
    Deeks, Alexandra S.
    Pollard, Andrew J.
    Brown, Anthony
    Rowland-Jones, Sarah L.
    Mongkolsapaya, Juthathip
    Barnes, Eleanor
    Hopkins, Susan
    Hall, Victoria
    CELL, 2021, 184 (23) : 5699 - +
  • [6] Immunogenicity of a BNT162b2 vaccine booster in health-care workers
    Saiag, Esther
    Goldshmidt, Hanoch
    Sprecher, Eli
    Ben-Ami, Ronen
    Bomze, David
    LANCET MICROBE, 2021, 2 (12): : E650 - E650
  • [7] Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence
    Daungsupawong, H.
    Wiwanitkit, V.
    MEDICINA DE FAMILIA-SEMERGEN, 2024, 50 (04):
  • [8] Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
    Murdoch, Louise
    Quan, Karen
    Baber, James A.
    Ho, Agnes W. Y.
    Zhang, Ying
    Xu, Xia
    Lu, Claire
    Cooper, David
    Koury, Kenneth
    Lockhart, Stephen P.
    Anderson, Annaliesa S.
    Tuereci, Ozlem
    Sahin, Ugur
    Swanson, Kena A.
    Gruber, William C.
    Kitchin, Nicholas
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (09) : 2241 - 2258
  • [9] Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
    Louise Murdoch
    Karen Quan
    James A. Baber
    Agnes W. Y. Ho
    Ying Zhang
    Xia Xu
    Claire Lu
    David Cooper
    Kenneth Koury
    Stephen P. Lockhart
    Annaliesa S. Anderson
    Özlem Türeci
    Uğur Şahin
    Kena A. Swanson
    William C. Gruber
    Nicholas Kitchin
    Infectious Diseases and Therapy, 2023, 12 : 2241 - 2258
  • [10] Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
    Yaniv Lustig
    Tal Gonen
    Lilac Meltzer
    Mayan Gilboa
    Victoria Indenbaum
    Carmit Cohen
    Sharon Amit
    Hanaa Jaber
    Ram Doolman
    Keren Asraf
    Carmit Rubin
    Ronen Fluss
    Ella Mendelson
    Laurence Freedman
    Gili Regev-Yochay
    Yitshak Kreiss
    Nature Immunology, 2022, 23 : 940 - 946